EGFR and hepatocellular carcinoma: However the SEARCH (Sorafenib and Erlotinib, a Randomized Trial Protocol for the Treatment of Patients With Hepatocellular Carcinoma) trial, the only phase III clinical trial including an EGFR inhibitor, was unable to reveal an improvement in survival of patients with advanced HCC by combining erlotinib and sorafenib [195].